Results 111 to 120 of about 100,489 (213)

Overcoming barriers, driving progress: Clinical science at IAS 2025

Journal of the International AIDS Society, Volume 29, Issue 3, March 2026.
Abstract Introduction The 13th IAS Conference on HIV Science, held in Kigali, Rwanda (13–17 July 2025), highlighted key advances in clinical research. Presentations focused on sustaining HIV treatment and prevention amid financial constraints, innovations in long‐acting oral antiretrovirals, and the management of comorbidities and co‐infections ...
Ezequiel Cordova, Simiso Sokhela, Jasmini Alagaratnam, Juan Ambrosioni   +3 more
wiley   +1 more source

Highly active antiretroviral therapy induced adverse drug reactions in Indian human immunodeficiency virus positive patients (RETRACTED by plagiarism)

Pharmacy Practice, 2011
THIS ARTICLE WAS RETRACTED AFTER A PLAGIARISM INVESTIGATIONObjective: To assess the incidence, severity pattern, causality, predictability and preventability of adverse drug reactions (ADRs) and to identify risk factors for adverse drug reactions in ...
Rajesh R, Vidyasagar S, Nandakumar K
doaj  

CD4‐Based Chimeric Antigen Receptor (CAR)‐T Cells With Resistance to HIV‐1 Infection and Enhanced Anti‐HIV Efficacy: Covalent Interaction Between CD4‐CAR and HIV‐1 Envelope Glycoprotein

Journal of Medical Virology, Volume 98, Issue 3, March 2026.
ABSTRACT The current highly active antiretroviral therapy (HAART or ART) effectively suppresses de novo HIV‐1 infection but fails to eliminate HIV reservoir cells, which leads to rapid viral rebound upon ART cessation. Chimeric antigen receptor (CAR) T cells engineered to target HIV‐1 Env⁺ cells offer a promising strategy to eliminate or control these ...
Yaoxian Lou, Xiuting He, Guangming Li, Martin Sikhondze, Jianping Ma, Hongwei Du, Xin Ouyang, Gianpietro Dotti, Mohammad Sajadi, Lishan Su   +9 more
wiley   +1 more source

Clinical, demographic and laboratory parameters at HAART initiation associated with decreased post-HAART survival in a U.S. military prospective HIV cohort

AIDS Research and Therapy, 2012
Background Although highly active antiretroviral therapy (HAART) has improved HIV survival, some patients receiving therapy are still dying. This analysis was conducted to identify factors associated with increased risk of post-HAART mortality.
Lifson Alan R, Krantz Elizabeth M, Grambsch Patricia L, Macalino Grace E, Crum-Cianflone Nancy F, Ganesan Anuradha, Okulicz Jason F, Eaton Anne, Powers John H, Eberly Lynn E, Agan Brian K   +10 more
doaj   +1 more source

The Next Frontier: Micro/Nanorobots Operating Inside the Living Body

SmartBot, Volume 2, Issue 1, March 2026.
Micro/nanorobots, with their tiny size and controllable motion capabilities, can perform complex and precise tasks in micro‐spaces, thus showing broad application prospects in the biomedical field. This review systematically summarizes the core advantages of micro/nanorobots in real‐time in vivo imaging, targeted drug delivery, and active barrier ...
Ningbo Yu, Jie Yang, Zicheng Ni, Yuepeng Cai, Beatriz Jurado‐Sánchez, Renfeng Dong   +5 more
wiley   +1 more source

Dyslipidemia in AIDS patients on highly active antiretroviral therapy

Brazilian Journal of Infectious Diseases
Highly active antiretroviral therapy (HAART) reduces AIDS-related morbidity and mortality, however it has been associated with metabolic abnormalities. This study estimated the prevalence of lipid abnormalities and related factors among patients on HAART.
Max Weyler Nery, Celina Maria Turchi Martelli, Marília Dalva Turchi   +2 more
doaj   +1 more source

Financing structural interventions: going beyond HIV-only value for money assessments.

, 2014
OBJECTIVE: Structural interventions can reduce HIV vulnerability. However, HIV-specific budgeting, based on HIV-specific outcomes alone, could lead to the undervaluation of investments in such interventions and suboptimal resource allocation.
Luna, Jorge, Lutz, Brian, Remme, Michelle, Vassall, Anna, Watts, Charlotte   +4 more
core   +1 more source

India's Health Diplomacy: Advancing Pharmaceutical and MedTech Leadership in the Global South

World Medical &Health Policy, Volume 18, Issue 1, March 2026.
ABSTRACT Health diplomacy has become a pivotal aspect of India's engagement with the Global South, intertwining foreign policy, public health, and global collaboration to address disparities while pursuing strategic interests. India's pharmaceutical industry, which accounts for nearly 20% of the world's generics, has positioned the nation as the ...
Gaurav Chanderprakash Mittal, Vijay Kumar Chattu, Prakash Narayanan, Rahul Clare, Cherian Varghese   +4 more
wiley   +1 more source

Altered Cytokine‐Induced STAT3 and STAT5 Activation of Peripheral T Follicular Helper Cells Contributes to Vaccine‐Non‐Responsiveness in Aging and HIV

Aging Cell, Volume 25, Issue 3, March 2026.
Chronic immune activation and inflammation associated with aging and HIV skew Tfh signaling toward enhanced IL‐2–STAT5 activation, reinforcing IL‐2R expression through a positive feedback loop and suppressing Tfh helper differentiation programs, thereby contributing to impaired vaccine responsiveness.
Sheldon Davis, Jonah Kupritz, Prabhsimran Singh, Savita Pahwa, Suresh Pallikkuth   +4 more
wiley   +1 more source

Substance Use and Sex Index version 2 (SUSI‐2): Validation of a brief questionnaire for the measurement of behaviours associated with transmission of blood borne viruses and sexually transmitted infections

Addiction, Volume 121, Issue 3, Page 670-679, March 2026.
Abstract Aims This study sought to validate a community‐acceptable Substance Use & Sex Index (SUSI) for use in substance use intervention research. SUSI aims to measure behaviours associated with the transmission of blood‐borne viruses (BBV) and sexually transmitted infections (STI) among people who use substances and incorporate contemporary sexual ...
Brendan Clifford, Raimondo Bruno, Liam Acheson, Michael E. Cecilio, Krista J. Siefried, Jack Freestone, Vincent J. Cornelisse, Brendan Crozier, Nicky Bath, Nadine Ezard   +9 more
wiley   +1 more source